PureTech Health (PRTC) Provides End of Year Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to PureTech Health (PRTC) Provides End of Year Update

PureTech Provides End of Year Report on Key Progress

December 22, 2022 2:00 AM EST

Rapid advancement of PureTechs Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone). Robust dose escalation and safety data also announced from completed monotherapy portion of Phase 1 program for LYT-200 (anti-galectin-9 mAb)

Catalyst-rich 2023 anticipated, with results from late-stage trial of LYT-100 in idiopathic pulmonary fibrosis and Phase 1b trial of LYT-200 in leukemia. Initiation of clinical trials planned with LYT-300 and LYT-310 (oral cannabidiol) targeting... More